Table 3 Summary of the risk of hypertension associated with PARP inhibitors

PARP inhibitors

  Olaparib

Olaparib plus cediranib regimen

8.78(5.39,14.29)

 < 0.01

0%

Fixed

6.50(3.50,12.05)

 < 0.01

0%

Fixed

Olaparib (exclude olaparib plus cediranib regimen)

200 mg-600 mg/day

0.79(0.69,0.89)

 < 0.01

22%

Fixed

0.61(0.48,0.77)

 < 0.01

0%

Fixed

800 mg/day

2.71(1.10,6.69)

0.03

23%

Fixed

/

All dose

0.82(0.72,0.92)

 < 0.01

38%

Fixed

0.61(0.48,0.77)

 < 0.01

0%

Fixed

Olaparib (include olaparib plus cediranib regimen)

1.12(0.67,1.87)

0.67

86%

Random

1.08(0.45,2.61)

0.86

79%

Random

  Veliparib

1.01(0.80,1.28)

0.94

3%

Fixed

0.77(0.32,1.83)

0.55

0%

Fixed

  Niraparib

3.47(2.36,5.09)

 < 0.01

21%

Fixed

4.20(2.04,8.68)

 < 0.01

0%

Fixed

  Rucaparib

0.90(0.56,1.45)

0.67

16%

Fixed

0.77(0.34,1.74)

0.53

15%

Fixed

  Iniparib

/

/

Cancer type

  Ovarian cancer

1.68(0.98,2.86)

1.54(0.93,2.55)

0.10

91%

Random

1.59(0.68,3.69)

0.28

84%

Random

  Lung cancer

0.79(0.33,1.90)

0.59

62%

Random

1.11(0.45,2.75)

0.83

37%

Fixed

  Breast cancer

1.21(0.85,1.73)

0.41

23%

Fixed

1.09(0.42,2.78)

0.86

0%

Fixed

  Prostate cancer

0.78(0.45,1.35)

0.38

0%

Fixed

0.70(0.23,2.10)

0.52

0%

Fixed

  Pancreatic cancer

1.17(0.52,2.62)

0.71

0%

Fixed

/

Treatment regime

  PARP versus Placebo

1.47(0.80,2.70)

0.22

78%

Random

1.37(0.57,3.29)

0.48

60%

Random

  PARP + Other anticancer drugs versus Other anticancer drugs

1.19(0.78,1.80)

0.42

87%

Random

1.37(0.55,3.40)

0.50

84%

Random

  PARP versus Other anticancer drugs

1.26(0.77,2.05)

0.35

48%

Fixed

0.40(0.16,1.00)

0.05

0%

Fixed

Total

1.22(0.91,1.65)

0.19

81%

Random

1.24(0.74,2.08)

0.42

68%

Random